Jonathan Robertson

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

Aili L. Lazaar, Lucy Yang, Rebecca Boardley et al. · British Journal of Clinical Pharmacology · 2015 · 171 citations · Full text

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

Praveen Anand, Ravikiran Shenoy, Joanne Palmer et al. · European Journal of Pain · 2011 · 166 citations

Pain Therapy, Pain Medicine, Neuropathic Pain +18

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

Anthony Cahn, Simon T. Hodgson, Robert C. Wilson et al. · BMC Pharmacology and Toxicology · 2013 · 52 citations · Full text

Asthma, Inflammatory Lung Disease, Lung Inflammation +19

Efficacy of Vestipitant, A Neurokinin-1 Receptor Antagonist, in Primary Insomnia

Emiliangelo Ratti, David Carpenter, Stefano Zamuner et al. · SLEEP · 2013 · 46 citations · Full text

Clinical Efficacy and Tolerability of a Novel Selective Corticosteroid in Atopic Dermatitis - Two Randomised Controlled Trials

Sabine Dölle, Nadine Hielscher, Philippe Bareille et al. · Skin Pharmacology and Physiology · 2015 · 13 citations

Novel Selective Corticosteroid, Allergy, Atopic Dermatitis +14